<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang T</submitter><funding>NIA NIH HHS</funding><funding>National Institute on Aging</funding><pagination>555-558.e1</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10089770</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(4)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>More than two-thirds of assisted living (AL) residents have dementia or cognitive impairment and antipsychotics are commonly prescribed for behavioral disturbances. As AL communities are regulated by state-level policies, which vary significantly regarding the care for people with dementia, we examined how antipsychotic prescribing varied across states among AL residents with dementia.&lt;h4>Design&lt;/h4>This was an observational study using 20% sample of national Medicare data in 2017.&lt;h4>Setting and participants&lt;/h4>The study cohort included Medicare beneficiaries with dementia aged 65 years or older who resided in larger (≥25-bed) ALs in 2017.&lt;h4>Methods&lt;/h4>The study outcome was the percentage of eligible AL person-months in which antipsychotics were prescribed for each s</pubmed_abstract><journal>Journal of the American Medical Directors Association</journal><pubmed_title>State Variation in Antipsychotic Use Among Assisted Living Residents With Dementia.</pubmed_title><pmcid>PMC10089770</pmcid><funding_grant_id>R01AG065722</funding_grant_id><funding_grant_id>R21 AG061632</funding_grant_id><funding_grant_id>R01 AG057746</funding_grant_id><funding_grant_id>R21AG061632</funding_grant_id><funding_grant_id>P01 AG027296</funding_grant_id><funding_grant_id>RF1 AG061221</funding_grant_id><funding_grant_id>RF1AG061221</funding_grant_id><funding_grant_id>K08 AG071856</funding_grant_id><funding_grant_id>R24 AG064025</funding_grant_id><funding_grant_id>R01 AG065722</funding_grant_id><funding_grant_id>R24AG064025</funding_grant_id><pubmed_authors>Shireman TI</pubmed_authors><pubmed_authors>Zhang T</pubmed_authors><pubmed_authors>Lo D</pubmed_authors><pubmed_authors>Varma H</pubmed_authors><pubmed_authors>Gerlach LB</pubmed_authors><pubmed_authors>Bynum JPW</pubmed_authors><pubmed_authors>Coe AB</pubmed_authors><pubmed_authors>Thomas KS</pubmed_authors><pubmed_authors>Joshi R</pubmed_authors><pubmed_authors>Zullo AR</pubmed_authors><pubmed_authors>Daiello LA</pubmed_authors></additional><is_claimable>false</is_claimable><name>State Variation in Antipsychotic Use Among Assisted Living Residents With Dementia.</name><description>&lt;h4>Objectives&lt;/h4>More than two-thirds of assisted living (AL) residents have dementia or cognitive impairment and antipsychotics are commonly prescribed for behavioral disturbances. As AL communities are regulated by state-level policies, which vary significantly regarding the care for people with dementia, we examined how antipsychotic prescribing varied across states among AL residents with dementia.&lt;h4>Design&lt;/h4>This was an observational study using 20% sample of national Medicare data in 2017.&lt;h4>Setting and participants&lt;/h4>The study cohort included Medicare beneficiaries with dementia aged 65 years or older who resided in larger (≥25-bed) ALs in 2017.&lt;h4>Methods&lt;/h4>The study outcome was the percentage of eligible AL person-months in which antipsychotics were prescribed for each s</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-04T19:58:12.74Z</modification><creation>2025-04-04T19:58:12.74Z</creation></dates><accession>S-EPMC10089770</accession><cross_references><pubmed>36841263</pubmed><doi>10.1016/j.jamda.2023.01.014</doi></cross_references></HashMap>